266 related articles for article (PubMed ID: 27567832)
21. High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases.
Bougea A; Stefanis L; Emmanouilidou E; Vekrelis K; Kapaki E
J Neural Transm (Vienna); 2020 Mar; 127(3):311-322. PubMed ID: 31912280
[TBL] [Abstract][Full Text] [Related]
22. Associations of Neuropsychiatric Features with Cerebrospinal Fluid Biomarkers of Amyloidogenesis and Neurodegeneration in Dementia with Lewy Bodies Compared with Alzheimer's Disease and Cognitively Healthy People.
de Oliveira FF; Miraldo MC; de Castro-Neto EF; de Almeida SS; Matas SLA; Bertolucci PHF; Naffah-Mazzacoratti MDG
J Alzheimers Dis; 2021; 81(3):1295-1309. PubMed ID: 33935098
[TBL] [Abstract][Full Text] [Related]
23. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia.
Spies PE; Slats D; Sjögren JM; Kremer BP; Verhey FR; Rikkert MG; Verbeek MM
Curr Alzheimer Res; 2010 Aug; 7(5):470-6. PubMed ID: 20043812
[TBL] [Abstract][Full Text] [Related]
24. Differential associations of clinical features with cerebrospinal fluid biomarkers in dementia with Lewy bodies and Alzheimer's disease.
de Oliveira FF; Miraldo MC; de Castro-Neto EF; de Almeida SS; Matas SLA; Bertolucci PHF; Naffah-Mazzacoratti MDG
Aging Clin Exp Res; 2023 Aug; 35(8):1741-1752. PubMed ID: 37264166
[TBL] [Abstract][Full Text] [Related]
25. Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach.
van Steenoven I; Koel-Simmelink MJA; Vergouw LJM; Tijms BM; Piersma SR; Pham TV; Bridel C; Ferri GL; Cocco C; Noli B; Worley PF; Xiao MF; Xu D; Oeckl P; Otto M; van der Flier WM; de Jong FJ; Jimenez CR; Lemstra AW; Teunissen CE
Mol Neurodegener; 2020 Jun; 15(1):36. PubMed ID: 32552841
[TBL] [Abstract][Full Text] [Related]
26. The value of cerebrospinal fluid α-synuclein and the tau/α-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology.
Førland MG; Tysnes OB; Aarsland D; Maple-Grødem J; Pedersen KF; Alves G; Lange J
Eur J Neurol; 2020 Jan; 27(1):43-50. PubMed ID: 31293044
[TBL] [Abstract][Full Text] [Related]
27. Homovanillic acid and 5-hydroxyindole acetic acid as biomarkers for dementia with Lewy bodies and coincident Alzheimer's disease: An autopsy-confirmed study.
Morimoto S; Takao M; Hatsuta H; Nishina Y; Komiya T; Sengoku R; Nakano Y; Uchino A; Sumikura H; Saito Y; Kanemaru K; Murayama S
PLoS One; 2017; 12(2):e0171524. PubMed ID: 28166276
[TBL] [Abstract][Full Text] [Related]
28. Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease.
Morenas-Rodríguez E; Alcolea D; Suárez-Calvet M; Muñoz-Llahuna L; Vilaplana E; Sala I; Subirana A; Querol-Vilaseca M; Carmona-Iragui M; Illán-Gala I; Ribosa-Nogué R; Blesa R; Haass C; Fortea J; Lleó A
Sci Rep; 2019 May; 9(1):7803. PubMed ID: 31127154
[TBL] [Abstract][Full Text] [Related]
29. Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease.
Kasuga K; Tokutake T; Ishikawa A; Uchiyama T; Tokuda T; Onodera O; Nishizawa M; Ikeuchi T
J Neurol Neurosurg Psychiatry; 2010 Jun; 81(6):608-10. PubMed ID: 20522869
[TBL] [Abstract][Full Text] [Related]
30. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort.
Schoonenboom NS; Reesink FE; Verwey NA; Kester MI; Teunissen CE; van de Ven PM; Pijnenburg YA; Blankenstein MA; Rozemuller AJ; Scheltens P; van der Flier WM
Neurology; 2012 Jan; 78(1):47-54. PubMed ID: 22170879
[TBL] [Abstract][Full Text] [Related]
31. A Comparison of Cerebrospinal Fluid Beta-Amyloid and Tau in Idiopathic Normal Pressure Hydrocephalus and Neurodegenerative Dementias.
Said HM; Kaya D; Yavuz I; Dost FS; Altun ZS; Isik AT
Clin Interv Aging; 2022; 17():467-477. PubMed ID: 35431542
[TBL] [Abstract][Full Text] [Related]
32. Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies.
Mollenhauer B; Bibl M; Wiltfang J; Steinacker P; Ciesielczyk B; Neubert K; Trenkwalder C; Otto M
Clin Chem Lab Med; 2006; 44(2):192-5. PubMed ID: 16475906
[TBL] [Abstract][Full Text] [Related]
33. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y
J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
[TBL] [Abstract][Full Text] [Related]
34. Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration.
Ishiki A; Kamada M; Kawamura Y; Terao C; Shimoda F; Tomita N; Arai H; Furukawa K
J Neurochem; 2016 Jan; 136(2):258-61. PubMed ID: 26485083
[TBL] [Abstract][Full Text] [Related]
35. Neuropsychiatric symptoms and α-Synuclein profile of patients with Parkinson's disease dementia, dementia with Lewy bodies and Alzheimer's disease.
Bougea A; Stefanis L; Paraskevas GP; Emmanouilidou E; Efthymiopoulou E; Vekrelis K; Kapaki E
J Neurol; 2018 Oct; 265(10):2295-2301. PubMed ID: 30083953
[TBL] [Abstract][Full Text] [Related]
36. Low levels of soluble NG2 in cerebrospinal fluid from patients with dementia with Lewy bodies.
Nielsen HM; Hall S; Surova Y; Nägga K; Nilsson C; Londos E; Minthon L; Hansson O; Wennström M
J Alzheimers Dis; 2014; 40(2):343-50. PubMed ID: 24448788
[TBL] [Abstract][Full Text] [Related]
37. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
[TBL] [Abstract][Full Text] [Related]
38. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.
Alves G; Brønnick K; Aarsland D; Blennow K; Zetterberg H; Ballard C; Kurz MW; Andreasson U; Tysnes OB; Larsen JP; Mulugeta E
J Neurol Neurosurg Psychiatry; 2010 Oct; 81(10):1080-6. PubMed ID: 20547614
[TBL] [Abstract][Full Text] [Related]
39. The combined effect of amyloid-β and tau biomarkers on brain atrophy in dementia with Lewy bodies.
Abdelnour C; Ferreira D; Oppedal K; Cavallin L; Bousiges O; Wahlund LO; Hort J; Nedelska Z; Padovani A; Pilotto A; Bonanni L; Kramberger MG; Boada M; Westman E; Pagonabarraga J; Kulisevsky J; Blanc F; Aarsland D
Neuroimage Clin; 2020; 27():102333. PubMed ID: 32674011
[TBL] [Abstract][Full Text] [Related]
40. Changes of cerebrospinal fluid Aβ
Hu X; Yang Y; Gong D
Neurol Sci; 2017 Nov; 38(11):1953-1961. PubMed ID: 28808876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
